Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Oxurion Announces Extraordinary and Annual Shareholders’ Meetings

1 Apr 2022

Leuven, Belgium, Boston, MA, US - April 1, 2022 – 07.00 PM CET - Regulated Information Oxurion NV (Euronext Brussels: OXUR)(the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announces extraordinary and annual shareholders’ meetings to be held on Tuesday 3 May 2022 at 10:00 AM (CET) and 2:00 PM (CET), respectively.

The convening notice and other documents pertaining to the shareholders’ meetings can be consulted on our website Oxurion/shareholders.

Press release attachment: 
Tags: 
Regulated information